Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Cholangiocarcinoma
Would you consider using enasidenib off-label for a cholangiocarcinoma with IDH2 mutation that has progressed on numerous lines of standard of therapy?
Related Questions
Would you administer adjuvant chemotherapy for extrahepatic cholangiocarcinoma that has received neoadjuvant therapy and achieved near CR?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
How would you approach a case of enteroblastic cholangiocarcinoma?
Do you incorporate the ALASCCA trial into your clinical practice and perform NGS on all early stage colon cancer patients to determine if adjuvant aspirin would be beneficial?
Do you always send for SDHB by IHC for workup of GIST? or is NGS/FISH that includes SDHB sufficient?
Would you add immunotherapy to FOLFOX if the patient is not a FLOT candidate for neoadjuvant gastric cancer, extrapolating data from the MATTERHORN study?
Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?
